Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

161. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

162. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis

Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

163. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Full Text available with Trip Pro

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cotte FE, De Pouvourville G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of osteoporosis treatment with oral bisphosphonates focusing on the issue of poor persistence in post-menopausal women. The authors concluded that improving persistence with oral bisphosphonate was likely to improve health benefits and reduce costs compared to current levels of treatment adherence

2011 NHS Economic Evaluation Database.

164. Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and meta-analysis

Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

165. Odanacatib for post-menopausal osteoporosis ? first or second line

Odanacatib for post-menopausal osteoporosis ? first or second line Odanacatib for post-menopausal osteoporosis – first or second line Odanacatib for post-menopausal osteoporosis – first or second line NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Odanacatib for post-menopausal osteoporosis – first or second line. Birmingham (...) : National Horizon Scanning Centre (NHSC). Horizon Scanning Review. 2011 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biphenyl Compounds; Osteoporosis, Postmenopausals Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90

2011 Health Technology Assessment (HTA) Database.

166. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women Full Text available with Trip Pro

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women Nayak S, Roberts MS, Greenspan SL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to assess the cost-effectiveness of various screening strategies for osteoporosis in postmenopausal women. The authors concluded that many strategies for screening were cost-effective, including strategies involving screening initiation at age 55 years. No strategy substantially outperformed another. Overall quality of the study

2011 NHS Economic Evaluation Database.

167. [A study on the evaluation standards of osteoporosis in Korea]

[A study on the evaluation standards of osteoporosis in Korea] [A study on the evaluation standards of osteoporosis in Korea] [A study on the evaluation standards of osteoporosis in Korea] Ahn J, Hyun MK, Kim Y, Suh HS, Park S, Park J, Sung YK, Lee EK Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ahn J, Hyun MK, Kim Y, Suh HS, Park S (...) , Park J, Sung YK, Lee EK. [A study on the evaluation standards of osteoporosis in Korea] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-10-002. 2011 Authors' conclusions The budget impact of the osteoporosis coverage extension plan was suggested to be 147 billion Korean won in the 2009 plan and 133.3 billion Korean won in the 2010 plan (the coverage will be extended to the lowest T-score less than -2.5 and one year coverage (scenario 2)) After adjusting for significant

2011 Health Technology Assessment (HTA) Database.

168. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Full Text available with Trip Pro

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L CRD summary The authors concluded that indirect treatment comparisons (...) indicated teriparatide, zoledronic acid and denosumab had the highest probabilities of being most efficacious for non-vertebral and vertebral fractures. In the absence of direct comparisons, the evidence presented may be the best available. However, the authors' conclusions should be considered tentative given limitations of the evidence and synthesis. Authors' objectives To compare the efficacy of nine osteoporosis medications for reducing fractures in post-menopausal women. Searching Seven databases

2011 DARE.

169. Bisphosphonates for Osteoporosis. Full Text available with Trip Pro

Bisphosphonates for Osteoporosis. 21083387 2010 11 23 2011 02 11 1533-4406 363 21 2010 Nov 18 The New England journal of medicine N. Engl. J. Med. Bisphosphonates for osteoporosis. 2027-35 10.1056/NEJMct1004903 Favus Murray J MJ Department of Medicine, University of Chicago, Chicago, IL 60637, USA. mfavus@medicine.bsd.uchicago.edu eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2011 Feb 10;364(6 (...) ):583; author reply 583-4 21306266 N Engl J Med. 2011 Feb 10;364(6):582-3; author reply 583-4 21306267 Aged Bone Density Conservation Agents chemistry pharmacology therapeutic use Diphosphonates chemistry pharmacology therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy physiopathology Structure-Activity Relationship 2010 11 19 6 0 2010 11 19 6 0 2010 12 14 6 0 ppublish 21083387 10.1056/NEJMct1004903

2010 NEJM

170. Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis. Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial Full Text available with Trip Pro

Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis. Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke. Both doses of lasofoxifene increased (...) the risk of venous thromboembolic events. In this report, we provide comprehensive cardiovascular end-point data, including component events comprising the composite end point of major CHD events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different categories of CHD risk.In this study, 8556 women 59 to 80 years of age with osteoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years. Cardiovascular events, including major CHD events

2010 EvidenceUpdates Controlled trial quality: predicted high

171. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada Full Text available with Trip Pro

Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada 20624868 2010 09 27 2018 11 13 1488-2329 182 12 2010 Sep 07 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. E610-8 10.1503/cmaj.080663 Hanley David A DA Departments of Medicine, University of Calgary, Calgary, AB, Canada. dahanley@ucalgary.ca Cranney Ann (...) A Jones Glenville G Whiting Susan J SJ Leslie William D WD Cole David E C DE Atkinson Stephanie A SA Josse Robert G RG Feldman Sidney S Kline Gregory A GA Rosen Cheryl C Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada eng Journal Article Practice Guideline Research Support, Non-U.S. Gov't Review 2010 07 12 Canada CMAJ 9711805 0820-3946 1406-16-2 Vitamin D A288AR3C9H 25-hydroxyvitamin D AIM IM Adult Bone Density drug effects Dietary Supplements adverse effects Fractures

2010 EvidenceUpdates

172. Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention Full Text available with Trip Pro

Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close (...) Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention Gustavo Duque, Jacqueline J Close, Julien P de Jager, Peter R Ebeling, Charles Inderjeeth, Stephen Lord, Andrew J McLachlan, Ian R Reid, Bruce R Troen and Philip N Sambrook Med J Aust 2010; 193 (3): 173-179. || doi: 10.5694/j.1326

2010 MJA Clinical Guidelines

174. Teriparatide (rDNA origin) injection - severe osteoporosis in women

Teriparatide (rDNA origin) injection - severe osteoporosis in women Common Drug Review CEDAC Meeting – January 20, 2010 Notice of CEDAC Final Recommendation – March 17, 2010 Page 1 of 5 © 2010 CADTH CEDAC FINAL RECOMMENDATION TERIPARATIDE ACP SUBMISSION (Forteo – Eli Lilly Canada Inc.) Indication: Severe Osteoporosis in Women Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that teriparatide not be listed. Reasons for the Recommendation: 1. Teriparatide costs (...) $15,688 per patient per 18 month course of treatment (the maximum length of time for which teriparatide treatment is recommended by Health Canada) based on its current list price, which is between 15 to 40 times the cost of bisphosphonates. Teriparatide has not been demonstrated to be cost-effective in any subgroup of post- menopausal women with severe osteoporosis. 2. There were no randomized controlled trials meeting the CDR systematic review protocol that evaluated teriparatide in women previously

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

175. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.

Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines

2010 American College of Preventive Medicine

176. Q&A Potpourri ? Osteoporosis, Vit D, Self-Monitoring of Blood Glucose, and Anti-Infectives

Q&A Potpourri ? Osteoporosis, Vit D, Self-Monitoring of Blood Glucose, and Anti-Infectives RxFiles Potpourri of Q&As Osteoporosis, Vitamin D, SMBG & Anti-infectives Oct 2010 OSTEOPOROSIS (OP) Should consideration be given to a “drug holiday” for patients on a bisphosphonate? ? Recent concerns about long-term treatment have raised the proposition of whether a “drug holiday” should be considered for bisphosphonate patients. 1,2,3 (See SDIS Bisphosphonate Safety 4 & the RxFiles OP Treatment Chart (...) that a supplement providing 500 – 1000mg of elemental calcium is enough for most, and some may not require any. Ö See Calcium Calculator tool(s) online 22,23 o Ensure adequate vitamin D intake and avoid excess calcium! Highlights 1) When deciding whether to treat osteoporosis (OP), assess fracture risk rather than BMD alone. 2) The benefit of bisphosphonates is generally considered to outweigh harms in OP patients who are truly “high risk”. However, patients at low- moderate risk of fracture may be receiving

2010 RxFiles

177. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society

Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 17, No. 1, pp. 23/24 DOI: 10.1097/gme.0b013e3181cdd4a7 * 2010 by The North American Menopause Society 5 Text printed on acid-free paper NAMS continuing medical education activity Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society This position (...) statement, which begins on page 25, has been designatedacontinuingmedicaleducation(CME)activityfrom The North AmericanMenopause Society(NAMS). GOAL To demonstrate an increase in, or affirmation of, current knowledge regarding the management of osteoporosis in postmenopausal women. LEARNING OBJECTIVES After reading this position statement, participants should be able to: & Describe the effect of menopause and aging on bone health. & Identify risk factors that contribute to fracture risk. & Discuss

2010 The North American Menopause Society

178. Osteodensitometry in primary and secondary osteoporosis

Osteodensitometry in primary and secondary osteoporosis IQWiG Reports – Commission No. D07-01 Osteodensitometry in primary and secondary osteoporosis 1 Executive Summary 1 Translation of the executive summary of the final report “Osteodensitometrie bei primärer und sekundärer Osteoporose” (Version 1.0; Status: 23.06.2010). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Executive summary of final report D07-01 Osteodensitometry in primary and secondary osteoporosis Version 1.0 23.06.2010 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Osteodensitometry in primary and secondary osteoporosis Contracting agency: Federal Joint Committee Commission awarded on: 10.05.2007 Internal Commission No.: D07-01 Publisher’s address: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel

2010 Institute for Quality and Efficiency in Healthcare (IQWiG)

179. Fracture prediction and the definition of osteoporosis in children and adolescents: the 2007 ISCD pediatric official positions.

Fracture prediction and the definition of osteoporosis in children and adolescents: the 2007 ISCD pediatric official positions. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You

2010 International Society for Clinical Densitometry

180. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD official positions.

Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD official positions. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures

2010 International Society for Clinical Densitometry